Hospice valuations rest on EBITDA multiples reflecting ADC volume, referral diversification, clinical team depth, and regulatory compliance. Calculate true EBITDA: take total revenue (patient-days × daily rate across all payers and care levels), subtract cost of goods sold (medical supplies, medications, equipment), subtract clinical payroll (RN, aide, social work, chaplaincy), subtract administrative payroll, subtract facility costs (office rent, utilities), subtract insurance (liability, cyber, directors & officers), then subtract administrative and operating costs. Your EBITDA is the baseline.

The 8x-16x EBITDA range reflects acquisition activity by large health systems and PE firms. A hospice generating $800K EBITDA with 120 ADC, diversified referrals, strong compliance record, and 60%+ RN retention trades closer to 12x ($9.6M) than 8x ($6.4M). The same hospice with 80 ADC and concentrated referrals trades closer to 8.5x-9.5x ($6.8M-$7.6M). ADC and diversification create 3-4x multiple variance.

Average daily census is the primary valuation anchor. A hospice with 120 ADC operating at $200 average daily rate generates $8.76M annual revenue (120 patients × 365 days × $200). At 35-45% EBITDA margins typical for hospice (higher than other healthcare due to care model efficiency), this generates $3.07M-$3.94M EBITDA. At 10x multiple (middle of range), this values at $30.7M-$39.4M. Conversely, an 80 ADC hospice generates $5.84M revenue and $2.04M-$2.63M EBITDA, valuing at $20.4M-$26.3M at same multiple. This 50% ADC difference creates 50% EBITDA and valuation difference.

Referral source diversification reduces valuation risk. Hospices where hospitals represent 50%+ ADC face catastrophic risk if hospital relationship changes. Ideal: referrals distributed broadly (10+ primary sources, no single source >25%). Model scenario: hospice with hospital 50% referrals loses hospital relationship, loses 50% ADC short-term, drives business to failure. Buyers specifically underwrite referral concentration; they interview top referral sources and analyze referral stability. Diversified referral hospices justify higher multiples.

Length of stay optimization affects reimbursement value. Hospices targeting 50-75 day average LOS optimize the benefit period structure. LOS under 30 days on average signals short-stay acute patients; LOS over 100 days signals long-stay chronic patients. Both have reimbursement efficiency implications. Calculate LOS by primary diagnosis (cancer, heart disease, dementia, COPD, other) and target diagnosis-appropriate LOS. Buyers model reimbursement impact of your current LOS composition.

Regulatory compliance is foundational. CMS surveys hospices every 3 years (or more frequently if complaints received). Deficiencies at scope/severity level C or higher trigger 20-40% valuation discount because they signal care quality or billing issues. Sanctions result in certification revocation and business failure. Clean survey history with zero or minor deficiencies (immediately corrected) justifies full valuation. Document survey history, any deficiencies, and corrective actions. Engage compliance officer to audit billing and documentation; prevent issues before surveys.

Clinical team retention directly impacts quality metrics and referral generation. Hospice quality metrics (patient/family satisfaction, symptom management, communication) drive referral patterns. Well-retained nursing teams with 3-5 year tenure demonstrate stable care quality. Turnover above 30% annually signals team stress or low satisfaction; buyers flag this. Compensation strategy matters: hospice RNs should earn within 5-10% of hospital RNs; this supports retention. Retention bonuses post-acquisition ($5-10K per RN for 2-year stay) protect clinical continuity.

Payer mix optimization affects revenue per patient-day. Hospices dominated by Medicare fee-for-service (highest rate, ~$220-240/day) have higher per-patient-day revenue than those with high Medicaid (lower rate, ~$140-160/day) or Medicare Advantage (capitated, ~$150-200/day). Model your payer mix impact: calculate weighted average daily rate. Hospices with favorable payer mix achieve higher revenue per ADC. Strategic growth toward Medicare Advantage (if you have scale to negotiate capitated rates effectively) and away from Medicaid improves profitability.

Buyers actively acquiring hospice companies include large health systems (UnitedHealth, Cigna, CVS Health), PE-backed platforms (Aveanna, Encompass Health), and hospice operators consolidating. Their acquisition targets are hospices with 80K+ ADC, diversified referrals (10+ sources), clean compliance record, and 60%+ RN retention. Health systems bid 9x-13x EBITDA. PE buyers bid 12x-16x EBITDA because they apply operational synergies and multi-site rollup strategies.

Timing matters. Hospice census fluctuates seasonally (winter peaks, summer dips); close valuations in fall/winter using prior full-year data so seasonality is normalized. A company showing strong winter census might appear overstated if valued in winter.

Regulatory and operational compliance includes CMS certification, state licensing, proper billing documentation, and compliance audit trails. Document all licenses, survey history, and billing audit results. Compliance gaps trigger discount requests.